ArticleFrontiers in immunology2025
A novel mitochondrial autophagy and aging-related gene signature for predicting ovarian cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pentachlorophenol enhances bladder cancer cell invasion through altered protein stability.iScience · 2026Article
- Identification of novel molecular subtypes in ovarian cancerThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC) is a highly malignant gynecologic tumor with a poor prognosis. In recent years, mitochondrial autophagy and aging (MiAg) have been recognized as crucial pathophysiological mechanisms leading to tumorigenesis. However, the expression of MiAg-related genes in OC and their correlation with prognosis remain unclear. In this study, we used multiple machine learning methods to identify 52 MiAg genes that were differentially expressed between OC and normal ovarian tissues. Based on these 52 differentially expressed genes (DEGs), 375 OC patients were classified into two subtypes by consensus clustering analysis. Subsequently, we evaluated the prognostic value of MiAg-related genes in relation to survival in 375 OC patients with complete survival information, and developed a MiAg prognostic score model. By applying Cox and LASSO regression methods, a five-gene signature was constructed, and the 375 OC patients in the TCGA cohort were categorized into low-risk and high-risk group based on the median risk score. Meanwhile, we categorized 174 OC patients from the Gene Expression Omnibus (GEO) database into high- and low-risk groups using the median risk score of the TCGA cohort to validate the MiAg scoring model. Furthermore, we analyzed these data with unifactorial and multifactorial analyses, functional enrichment analysis, gene mutation analysis, immune infiltration, drug susceptibility analysis, cell line analysis, and immunohistochemistry data from the HPA database. In conclusion, the MiAgscore predicted patient survival, and lower MiAgscore values were associated with a better survival advantage. A comprehensive assessment of mitochondrial autophagy and cellular senescence alterations in OC could help advance disease target development and provide more effective personalized treatment strategies for OC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.